FDA tells doctors new heparin formula less potent

Oct 01, 2009 By MATTHEW PERRONE , AP Business Writer

(AP) -- The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors.

The FDA said Thursday new heparin vials scheduled to begin shipping next week will be 10 percent less potent than the original blood thinner. The change is designed to make it easier for manufacturers to spot impurities in the drug, but it will require some adjustments by physicians who administer the drug.

"Health care providers should consider the change in potency of heparin when making decisions about which dose to administer," said Dr. John Jenkins, director of the FDA's office of new drugs. Doctors may need to use extra heparin to adequately treat some patients, he added.

The FDA said older vials of heparin will remain on the market after the new formula begins shipping Oct. 8. While having both on the market could cause confusion, the agency said it was necessary to ensure there is adequate supply of the drug.

U.S. Pharmacopeia, a nonprofit that defines standards for U.S. pharmaceuticals, set the new heparin formula guidelines.

Last year, contaminated heparin imported from China was linked to hundreds of life-threatening and more than 200 deaths. The drug was recalled by Baxter International and the U.S. blocked imports from the Chinese company that supplied the main ingredient.

The FDA determined that the heparin was contaminated with a nutritional supplement that costs less, but mimics the real drug in routine tests for potency. Agency inspectors suspected deliberate contamination.

Heparin, derived from a chemical in pig intestines, is used in , kidney dialysis and a variety of other medical procedures.

Most manufacturers of the drug will place an 'N' on the label of the new formulas to help health care providers tell the difference.

The four producers of in the U.S. are APP Pharmaceuticals, Hospira, Baxter and B.Braun.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: 'The process by which drugs are discovered and developed will be fundamentally different in the future'

add to favorites email to friend print save as pdf

Related Stories

FDA to test all heparin at U.S. border

Mar 16, 2008

The U.S. Food and Drug Administration has issued an import alert and plans to test all shipments of the drug heparin before they enter the country.

Baxter may stay out of Heparin business

Apr 25, 2008

The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.

Heparin recall spreads in Europe

Mar 27, 2008

France, Italy and Denmark are recalling heparin after an Italian firm purchased contaminated ingredients from China, EU drug regulators said.

Baxter issues urgent recall of Heparin

Jan 26, 2008

Baxter Healthcare has issued an urgent U.S. recall of nine lots of the injectable blood thinner heparin after reports of adverse patient reactions.

Recommended for you

Discount generic drug programs grow over time

16 hours ago

Generic discount drug programs (GDDPs, which charge nominal fees to fill prescriptions) have grown over time and their initial lower use by racial/ethnic minorities has evaporated, writes author Song Hee Hong, Ph.D., of the ...

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

User comments : 0